Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7547 USD | +0.62% | +0.49% | +2.68% |
2023 | NGM Biopharmaceuticals Says Phase 2b Trial of Potential Cirrhosis Treatment Meets Primary Endpoint | MT |
2023 | Alpine 4 Holdings, Inc.(NasdaqCM:ALPP) dropped from S&P Global BMI Index | CI |
Evolution of the average Target Price on Alpine 4 Holdings, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Alpine 4 Holdings, Inc.
Alliance Global Partners |
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ALPP Stock
- Consensus Alpine 4 Holdings, Inc.